Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025

公司将于2025年6月2日东部时间上午8:00举办视频网络直播

WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) --

马萨诸塞州沃特敦，2025年5月30日（环球新闻社）--

Kymera Therapeutics, Inc.

凯米拉治疗公司

(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025.

（纳斯达克股票代码：KYMR），一家处于临床阶段的生物制药公司，致力于推进一类用于免疫疾病的新口服小分子降解药物，将于2025年6月2日星期一公布在健康志愿者中评估KT-621单次和多次递增剂量的I期临床试验结果。

The Company will host a video webcast at 8:00 a.m. ET that day..

公司将于当天上午8:00（东部时间）举办视频网络直播。

To join the video call or view the livestreamed webcast, please register via this

要加入视频通话或观看直播的网络广播，请通过此链接注册

link

链接

,

，

or visit “

或访问“

News and Events

新闻与事件

” in the Investors section of the Company’s website at

“在公司网站的投资者部分 tại

www.kymeratx.com

www.kymeratx.com

. A replay of the webcast and copy of the presentation will be available following the event.

活动结束后，网络直播的回放和演讲稿的副本将会提供。

About STAT6 and KT-621

关于STAT6和KT-621

KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation. STAT6 degradation has the potential to provide the convenience of an oral medicine with the potential for biologics-like activity and in doing so reach broader patient populations compared to injectable biologics or other standards of care.

KT-621 是一种研究性、首创新药、每日一次的口服STAT6降解剂，STAT6是负责IL-4/IL-13信号传导的特定转录因子，也是Th2炎症的核心驱动因素。STAT6降解有望提供口服药物的便利性，同时具备类似生物制剂的活性，从而相较于注射类生物制剂或其他护理标准能够覆盖更广泛的患者群体。

In preclinical studies, KT-621 demonstrated dupilumab-like activity in several .

在临床前研究中，KT-621在多个方面表现出类似度普利尤单抗的活性。

in vitro

体外

and

和

in vivo

体内

models and was safe and well tolerated. KT-621, the first STAT6 directed medicine to enter clinical evaluation, has the opportunity to transform treatment paradigms for more than 130 million patients around the world, including children and adults, suffering from Th2 diseases such as AD, asthma, chronic obstructive pulmonary disease (COPD), prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), bullous pemphigoid (BP), and chronic spontaneous urticaria (CSU), among others..

模型中表现良好，安全且耐受性佳。KT-621 是首个进入临床评估的针对 STAT6 的药物，有望改变全球超过 1.3 亿患者的治疗模式，包括儿童和成人。这些患者患有 Th2 型疾病，如特应性皮炎 (AD)、哮喘、慢性阻塞性肺病 (COPD)、结节性痒疹 (PN)、伴鼻息肉的慢性鼻窦炎 (CRSwNP)、嗜酸性食管炎 (EoE)、大疱性类天疱疮 (BP) 和慢性自发性荨麻疹 (CSU) 等。

KT-621 is currently being evaluated in a Phase 1b trial (BroADen) in atopic dermatitis patients, with data from the study expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b clinical trials in moderate to severe AD and asthma patients are expected to begin in the fourth quarter of 2025 and the first quarter of 2026, respectively.

KT-621目前正在进行一项针对特应性皮炎患者的1b期临床试验（BroADen），预计该研究的数据将在2025年第四季度公布。两项平行的针对中重度特应性皮炎和哮喘患者的2b期临床试验预计分别于2025年第四季度和2026年第一季度开始。

These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications..

这些研究旨在加速 KT-621 的开发，并为后续针对多种 Th2 皮肤科、胃肠病学和呼吸系统适应症的平行 III 期注册研究选择剂量。

About Kymera Therapeutics

关于凯米拉治疗学

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics.

Kymera是一家处于临床阶段的生物技术公司，率先在靶向蛋白质降解（TPD）领域开展工作，致力于开发解决关键健康问题并有潜力显著改善患者生活的药物。Kymera正在利用TPD来应对传统疗法无法触及的疾病靶点和通路。

Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.

Kymera已将首个降解剂推进至免疫疾病临床阶段，目前专注于构建行业领先的口服小分子降解剂管线，为这些疾病的患者提供新一代便捷且高效的治疗方案。Kymera成立于2016年，过去几年一直被评为波士顿最佳工作场所之一。

For more information about our science, pipeline and people, please visit .

有关我们的科学、研发管线和人员的更多信息，请访问。

www.kymeratx.com

www.kymeratx.com

or follow us on

或关注我们

X

X

or

或

LinkedIn

领英

.

。

Availability of Other Information About Kymera Therapeutics

关于Kymera Therapeutics的其他信息的可用性

For more information, please visit the Kymera website at

欲了解更多信息，请访问 Kymera 网站：

https://www.kymeratx.com/

https://www.kymeratx.com/

or follow Kymera on

或关注 Kymera 的

X (@KymeraTx)

X (@KymeraTx)

and

和

LinkedIn (Kymera Therapeutics

领英 (Kymera Therapeutics)

). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on

). 投资者及其他人士应注意，Kymera通过公司网站与投资者和公众进行沟通，包括但不限于公司披露、投资者简报、常见问题解答、证券交易委员会（SEC）文件以及新闻稿，也包括在

X

X

and

和

LinkedIn

领英

. The information that Kymera posts on its website or on

。Kymera在其网站上发布的信息或

X

X

or

或

LinkedIn

领英

could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. .

可能被视为重要信息。因此，公司鼓励投资者、媒体及其他感兴趣的人士定期查阅 Kymera 在该处发布的信息。Kymera 网站或社交媒体的内容不应被视为以引用方式并入依据修订后的《1933年证券法》提交的任何文件中。

Investor and Media Contact:

投资者和媒体联系人：

Justine Koenigsberg

朱斯廷·科尼格斯伯格

Vice President, Investor Relations

投资者关系副总裁

investors@kymeratx.com

投资者@kymeratx.com

media@kymeratx.com

媒体@凯美拉科技公司

857-285-5300

857-285-5300